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Abstract 
Objective(s) 
Rapidly growing mycobacteria (RGM) are capable of producing diseases in humans. Since mycobacteria 
vary in their susceptibility, precise identification is critical for adoption of correct drug therapy. The main 
aim of this study was molecular identification and evaluation of antimicrobial susceptibility pattern of 
Iranian clinically isolated Myocbacterium fortuitum. 
Materials and Methods 
A total of 72 presumptively identified isolates of clinical atypical mycobacteria collected by Isfahan 
Research Center for Infectious Diseases & Tropical Medicine during 2006-2008 were included in the current 
study. A combination of conventional and molecular tests was applied to identify the isolates. Molecular 
methods including genus and group specific PCR and PCR-Restriction Algorithm (PRA) based on hsp65 
gene were applied to achieve exact identification of mycobacterial strains. Antimicrobial susceptibility 
testing on M. fortuitum isolates was performed by in-house prepared broth microdilution test.. 
Results 
Out of 72 collected atypical mycobacteria isolates, we identified 25 strains of M. fortuitum. All strains had 
the specific molecular markers of mycobacterial identity and similar species specific PRA pattern of the 
international type strain of M. fortuitum. Drug susceptibility testing showed that the M. fortuitum isolates are 
sensitive to amikacin, sulfamethoxazole and ciprofloxacin (100%), imipenem (92%), clarithromycin (76%), 
cefoxitin (56%) and doxycycline (16%). 
Conclusion 
Molecular identification of atypical mycobacteria based on PRA is a reliable and rapid approach which can 
identify mycobacterial strains to the species level. Our study showed that M. fortuitum plays a significant 
role in pulmonary and extrapulmonary infection in patients and should be given proper considerations when 
clinical samples are processed. 
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Introduction 
Rapidly growing mycobacteria (RGM) are 
ubiquitous in nature. The Mycobacterium 
fortuitum  group including M. fortuitum,  M. 
peregrinum,  M. fortuitum third biovariant 
complex, M. porcinium, and M. mageritense, 
M. chelonae, and M. abscessus are the species 
of RGM most often associated with human 
diseases. These organisms cause a variety of 
localized or disseminated diseases, particularly 
pulmonary as well as primary skin and soft 
tissue infections (1). 
Mycobacterial susceptibility testing is 
important for the management of patients 
with tuberculosis and those with a disease 
caused by certain non-tuberculous 
mycobacteria. Since mycobacterial species 
vary in their susceptibilities to antimicrobial 
agents, identification of atypical 
mycobacteria to the species level is critical 
in therapeutic outcome (2, 3). 
Classical identification of mycobacteria 
based on phenotypic tests may take several 
weeks, and often fail to provide a precise 
identification. During last decade, several 
molecular methods have been introduced for 
mycobacterial identification. Of these 
methods, PRA is preferred because of its 
rather simplicity and rapidity. PRA scheme 
targeting  heat shock protein 65 (hsp65) has 
been most widely used, since this molecule 
is conserved in all mycobacteria, while 
showing sufficient sequence variation to 
allow mycobacteria differentiation at the 
species level (4). 
In our country, Iran, It has been reported that 
M. fortuitum is the most frequent atypical 
mycobacteria isolated from clinical samples (5), 
however, to our knowledge there was not 
sufficient evidence to indicate the role it might 
play in Iranian clinical samples. Furthermore, we 
were unable to track down any information 
regarding the susceptibility pattern of Iranian       
M. fortuitum strains. For these reasons, we 
decided  to  show  a  more  precise  picture  of        
M. fortuitum infection in pulmonary and extra 
pulmonary diseases of Iranian patients from 
some parts of Iran  and assess the antibiotic 
susceptibility of the isolates to current 
therapeutic drugs. 
Materials and Methods 
Organisms 
A total of 72 isolates of atypical mycobacteria 
originating from clinical samples collected by 
Isfahan Infectious Diseases and Tropical 
Medicine Research Center (isolated from 
Isfahan), Pasture Institute of Iran (isolated 
from Tehran) and Isfahan Public Health Center 
(isolated from Isfahan) during 2006-2008 were 
included in the current study. Clinical isolates 
were initially identified as presumptive 
mycobacterial strains. The clinical sources of 
isolates were sputum, bronchial washing, 
pleural effusion, urine and skin wound. 
 
Identification of M. fortuitum isolates 
Conventional methods 
All isolates were investigated by conventional 
methods consisting of acid fast staining and 
analysis of phenotypic characteristics, i.e., 
growth on Lowenstein-Jensen (LJ) medium at 
25 °C, 37 °C and 45 °C, arylsulfatase activity, 
pigment production, growth rate (<7 days), 
nitrate reduction, growth on MacConkey agar 
without crystal violet, tolerance to 5% NaCl, 
iron uptake, existence of urease, tellurite 
reduction, semi quantitative and catalase 
activity at 68 ºC and niacin production tests. 
M. tuberculosis H37Rv, M. bovis  BCG  and         
M. kansassi (DSM 44162) were used as 
control strains for phenotypic tests. Isolates 
suspicious to be M. fortuitum were further 
investigated by molecular methods (6-8). 
 
Molecular methods 
DNA extraction 
Purified DNA was extracted by standard phenol-
chloroform extraction method (9). In brief, after 
thermal inactivation, the bacterial cells were 
treated with lysozyme and digested with 
proteinase K in the presence of sodium dodecyl 
sulfate. The high quality DNA was purified with 
phenol-chloroform and precipitated with 
isopropanol. The precipitate was dehydrated and 
dissolved in 50 µl of sterile double-distilled 
water and stored at -70 ºC. 
 
Genus and species specific PCR 
We used broad-spectrum genus and species 
specific PCR primer pairs (MGSf- 
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5’CTGGTCAAGGAAGGTCTGCG-3’, MGSr-
5’ GATGACACCCTCGTTGCCAAC-3’) and 
optimal amplification conditions as follows; the 
reaction mixture (50 µl) consisted of 2 µl of 
DNA template (20 ng), 5 µl of 10X PCR- buffer 
with MgCl2, 1 µl of mixed deoxynucleoside 
triphosphates (10 mM), 4 µl of each forward and 
reverse primers (10 pmol), 0.5 µl of Roche-Taq 
DNA polymerase (5 U/µl) and 33.5 µl of PCR 
Grade Water. The PCR program consisted of 30 
cycles of denaturing at 95 °C for 15 Sec, 
annealing at 58 °C for 15 sec, and extension at 
72 °C for 30 sec using Eppendroff PCR system 
(10).  M. tuberculosis H37Rv and M. kansassi 
(DSM 44162) were used as positive controls. A 
sample of complete mix plus DNA-free water 
was used as negative control. 
 
PCR-RFLP (PRA) 
The isolates were investigated by hsp65-PRA 
for precise identification of M. fortuitum. 
Having confirmed the successful amplification 
of the 644-bp PCR fragment, the product was 
subjected to restriction enzyme digestion by 
HphI, HpaII and AvaII enzymes. All reagents 
were obtained from Fermentas (Fermentas Inc, 
Germany). Digestion of the 644 bp hsp65 
fragment by enzymes was performed 
following the manufacture’s protocol (4). 
After digestion, products were electrophoresed 
in a 3% agarose gel. We used 50 bp DNA size 
marker to estimate the molecular weight sizes 
of the fragments. M. tuberculosis H37RV and 
M. kansasii (DSM 44162) were included in all 
experiments for interpretation of the PRA 
profiles. The size of the restriction fragments 
was generally species specific (4). 
 
Antimicrobial drug sensitivity test 
agar plate and incubated at 30 °C for 72 hr. 
Three to five similar colonies were transferred 
to a tube containing 4.5 ml of Middlebrook 
7H9 (from Difco, BBL™, US) and glass 
beads. The turbidity was adjusted until it 
matched that of a 0.5 McFarland standard by 
visual examination. 
The growth suspensions were mixed 
vigorously on a vortex for 15 to 20 sec. The 
final inoculum (approximately 5×10
5 CFU/ml) 
was prepared by transferring 50 µl of the 
suspension to a tube containing 10 ml of 
cation-adjusted Mueller-Hinton broth (from 
Merck; Darmstadt, Germany) and inverting the 
tube 8 to 10 times prior to use. 
 
Antimicrobial agents 
The antimicrobial agents used were amikacin 
(A1774), cefoxitin (C4786), ciprofloxacin 
(17850), imipenem (I0160), clarithromycin 
(C9742), doxycycline (D9891) and 
sulfamethoxazole (S7507) purchased from 
Sigma Aldrich Corp (Germany). We prepared 
in-house cation adjusted microdilution trays. The 
final range of concentrations of anti-
mycobacterial agents in the wells were as 
follows: 1 to 128 mg/ml for amikacin, 2 to 256 
mg/ml for cefoxitin, 0.125 to 16 mg/ml for 
ciprofloxacin, 0.03 to 64 mg/ml for 
clarithromycin, 0.25 to 32 mg/ml for 
doxycycline and 1 to 64 mg/ml for imipenem 
and sulfamethoxazole. Each flat bottomed tray 
also contained a positive growth control well. 
Having prepared a two-fold serial dilution of 
each antibiotic agent they were divided into the 
wells. The microdilution trays were sealed and 
stored at -70 °C temperature until they were 
used. MIC values and an interpretation based on 
the breakpoints for RGM are listed in Table 1. 
 
Inoculum preparation 
Each isolate was sub-cultured onto a sheep blood 
 
Table 1. Suggested broth microdilution breakpoints for rapidly growing mycobacteria by NCCLS 
MIC (µg/ml) for category  Antimicrobial agents 
Susceptible Intermediate  Resistant 
Amikacin  ≤16 32 ≥64 
Cefoxitin  ≤16 32–64  ≥128 
Ciprofloxacin  ≤1 2 ≥4 
Clarithromycin  ≤2 4 ≥8 
Doxycycline  ≤1 2-8  ≥16 
Imipenem  ≤4 8  ≥16 
Sulfamethoxazole  ≤32 – ≥64  
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Preparation of the assay plates 
Aliquots of 0.01 ml of final inoculum per well 
were dispensed into the assay plates. The 
inoculated trays were covered with an 
adhesive seal and incubated at 30 °C in 
ambient air. A sheep blood agar plate was also 
inoculated with a loopful of the final inoculum 
to check the purity. The trays were first 
examined after 72 hr by looking for 
macroscopic growth with an indirect light 
source. If no macroscopic growth was 
visualized, the trays were re-incubated and 
read daily thereafter (for up to 5 days) until 
moderate growth was visible. For all 
antibiotics but sulfamethoxazole, the MIC was 
defined as the lowest concentration that 
completely inhibited macroscopic growth. For 
sulfamethoxazole, the endpoint or MIC was 
defined as the concentration of the drug in the 
well with approximately 80% inhibition of 
growth compared to the growth in the control 
well with no drug (11-13). Susceptible and 
resistant breakpoints are listed in Table 3. 
 
Results 
In the current study out of a total of 72 atypical 
mycobacteria, 25 clinical isolates (21 isolates 
from Isfahan and 4 from Tehran) were 
identified as M. fortuitum. The sources of 
isolates  were  as  follows:  bronchial  washes         
(13  isolates),  urine  (6  isolates),  pleural  fluid          
(3 isolates), sputum (2 isolates) and skin 
wound (1 isolate). All isolated strains showed 
biochemical characteristics consistent with           
M. fortuitum complex. However, the isolates 
were not identified to the biovariant level. 
All  Iranian isolates showed phenotypic 
characteristics consistent with M. fortuitum, 
i.e., rapid growing (<7 days) at 25, 31, 37 °C 
and at 45 °C, no pigment production, growth 
on MacConkey agar without crystal violet and 
principal biochemical properties of catalase, 
tween hydrolysis, and arylsulfatase positivity. 
The presumptive M. fortuitum Iranian 
isolates were further analyzed and verified as 
mycobacteria using genus and group specific 
PCR targeting a 228 bp fragment (Figure 1). 
Furthermore with the application of the PRA 
algorithm targeting 644 bp hsp65 DNA, 
twenty five isolates were clearly distinguished 
from other mycobacteria. All isolates had the 
characteristic  AvaII (501, 119 bp), HphI         
(254, 207, 97 bp) and HpaII (270, 161, 117 
bp) PRA pattern of international type strain of 
M. fortuitum ATCC 6841T (Figure 2). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1. Genus specific amplification of atypical 
mycobacteria. Lanes 2-10; M. fortuitum clinical isolates, 
Lane 11: M.  kansassi DSM 44162, Lane 12: M. 
tuberculosis H37Rv strain. White arrows indicate group 
specific fragments for M. fortutitum and M. tuberculosis 
respectively.  Lane 1: The 50 bp DNA size marker. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2. The differentiation of M. fortuitum clinical 
isolates from other mycobacterial species by hsp65 PRA 
based on digestion of a 644 bp amplified fragment with 
AvaII, HphI and HpaII. Lanes 2, 3, 7, 8, 12 & 13: M. 
fortuitum; Lanes 4, 9 & 14: M. kansasii DSM 44162 and 
Lanes 5, 10 & 15: M. tuberculosis H37Rv. Lanes 1, 6, 
11 & 16: The 50-bp DNA size marker. 
 
 
 
Following  precise  identification  of                   
M. fortuitum isolates, they were subjected to 
standard susceptibility testing based on 
National Committee on Clinical Laboratory 
Standards (NCCLS) recommendations. All 
isolates grew well in the broth medium and 
produced sharp, easily discernible growth 
endpoints. The susceptibility pattern of M. 
fortuitum strains investigated by this study and 
MIC50 (MIC at which 50% of the isolates 
tested are inhibited), MIC90 and MIC values 
are shown in Table 2.  
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Table 2. Drug susceptibility testing of M. fortuitum isolates. 
  No.(%) of isolates  MIC (µg/ml) 
Drug Susceptible  Intermediate  Resistant  Range  50%  90% 
Amikacin  25 (100)  0 (0)  0 (0)  1-2  1  2 
Sulfamethoxazole  25 (100)  0 (0)  0 (0)  1-32  1  16 
Cefoxitin  14 (56)  3 (12)  8 (32)  4-256  16  128 
Doxycycline 4  (16)  11(44)  10  (40)  0.25-32  8  16 
Clarithromycin  19 (76)  2 (8)  4 (16)  0.06-16  1  4 
Ciprofloxacin  25 (100)  0 (0)  0 (0)  0.125-0.25  0.125  0.25 
Imipenem  23 (92)  2 (8)  0 (0)  1-16  1  4 
Discussion 
In the United States and many other countries 
it has been reported that M. avium complex is 
the most common atypical mycobacteria 
isolated from clinical samples (13). However 
in a multi-country retrospective survey by 
Martin-Casabona et al (2004) which included 
data from 14 countries including Iran, it was 
reported that the five most frequently isolated 
Non-tuberculous mycobacterial (NTM) 
species were M. avium complex, M. gordonae, 
M. xenopi, M. kansasii and M. fortuitum 
respectively. These five species accounted for 
87.6% of total NTM isolated (5). 
This report has also compared the results 
from different countries and concluded that 
except for Iran, Turkey, Belgium and the 
Czech Republic, the isolation rate of M. avium 
complex was above 20%. Interestingly, it has 
been showed that M. fortuitum was most 
frequent in Iran and Turkey comprising more 
than 53.9% and 33.9% of all NTM isolates, 
respectively (5). 
Despite increasing clinical significance of   
M. fortuitum, we found no information about 
drug susceptibility pattern of Iranian isolates. 
This was the reason why we decided to 
implement the current study. However, since 
our study included a small sample from certain 
regions of Iran the results cannot represent the 
whole country profile and might be interpreted 
as a pilot study. 
All our investigated isolates were susceptible 
to amikacin, ciprofloxacin and 
sulfamethoxazole. However susceptibility rate 
to imipenem, clarithromycin, cefoxitin and 
doxycycline were rather lower, i.e. 92%, 76%, 
56% and 16% respectively. According to a 
document published in 2007 by American 
Thoracic Society M. fortuitum isolates were 
100% susceptible to amikacin, ciprofloxacin 
ofloxacin, sulfonamides and imipenem, 80% 
to clarithromycin and 50% to cefoxitin and   
doxycycline (6). There are several papers from 
different countries in which susceptibility rates 
of M. fortuitum isolates to amikacin, 
imipenem, ciprofloxacin, clarithromycin, 
sulfonamides and cefoxitin are reported (96-
100%),  (62-98%),  (62-95%),  (30-84%),        
(6-85%) and (19-55%) respectively (1, 14-15). 
Based on literature review, different 
susceptibility patterns for currently prescribed 
antibiotics with the exception of amikacin had 
been reported from different countries (1, 14-
15). In comparison to other studies, our results 
showed  that  susceptibility  pattern  of              
M. fortuitum clinical isolates to amikacin, 
sulfamethoxazole, clarithromycin, cefoxitin 
and ciprofloxacin were in agreement with the 
rate reported by American thoracic society 
document, but susceptibility to doxycycline 
(16%) was much lower than that of obtained 
by this study. 
Some investigators believe that differences 
in antibiotic resistance rates in RGM may be 
the result of population or geographical 
differences or, probably, the method of 
susceptibility testing (15, 16). Despite 
limitations of current testing methods for 
RGM and lack of correlation between in vitro 
susceptibility and therapeutic responses, one 
might assume that in vitro resistance would 
foresee treatment failure (6, 16). However, 
there are large prospective studies assessing 
the correlation of in vitro susceptibility with 
therapeutic outcome indicating that 
susceptibility results for atypical mycobacteria 
should be interpreted cautiously. 
 
Conclusion 
In conclusion, we would like to emphasize that 
correct identification of M. fortuitum species 
needs a combination of phenotypic and  
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molecular tests. Furthermore, determination of 
susceptibility patterns of clinical isolates of      
M. fortuitum is subject to accurate identification 
of the isolates to the species level. 
In addition, since susceptibility patterns in 
RGM are unforeseeable with possible 
geographic differences; we are unable to 
recommend any antibiotic drug of choice for 
clinical management of patients. On the other 
hand, in view of M. fortuitum environmental 
source, further studies might include 
environmental isolates to have a better 
understanding of susceptibility patterns and 
resistance mechanism of M. fortuitum. 
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